SOPHiA GENETICS SA (SOPH): ANSOFF-Matrixanalyse

In der sich schnell entwickelnden Landschaft der Präzisionsdiagnostik erweist sich SOPHiA GENETICS SA als transformative Kraft, die die komplexe Marktdynamik durch eine sorgfältig ausgearbeitete Wachstumsstrategie strategisch steuert. Durch den Einsatz modernster KI-gesteuerter Genomtechnologien und eines vielfältigen Ansatzes, der Marktdurchdringung, Entwicklung, Produktinnovation und strategische Diversifizierung umfasst, ist das Unternehmen bereit, die Gesundheitsdiagnostik zu revolutionieren. Ihre kühne Vision überschreitet traditionelle Grenzen und verspricht, neu zu definieren, wie genetische Erkenntnisse personalisierte medizinische Lösungen in globalen Gesundheitsökosystemen vorantreiben.

SOPHiA GENETICS SA (SOPH) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie den Direktvertrieb, der auf Onkologie- und Diagnosezentren für seltene Krankheiten ausgerichtet ist

SOPHiA GENETICS SA meldete zum 31. Dezember 2022 40 Direktvertriebsmitarbeiter. Das Unternehmen strebt an, die Vertriebsmitarbeiter in den Märkten für Onkologie und Diagnose seltener Krankheiten um 25 % zu erhöhen.

Marktsegment	Aktuelle Vertriebsmitarbeiter	Zielwachstum
Onkologische Diagnostik	22	+8 Vertreter
Diagnostik seltener Krankheiten	18	+2 Vertreter

Verstärken Sie Ihre Marketingbemühungen, um KI-gesteuerte Präzisionsdiagnosefunktionen hervorzuheben

Zuweisung des Marketingbudgets für 2023: 4,2 Millionen US-Dollar, was einer Steigerung von 18 % gegenüber 2022 entspricht.

• Ausgaben für digitales Marketing: 1,8 Millionen US-Dollar
• Konferenz- und Eventmarketing: 1,3 Millionen US-Dollar
• Werbung für wissenschaftliche Veröffentlichungen: 600.000 US-Dollar
• Gezielte digitale Kampagnen: 500.000 US-Dollar

Bieten Sie bestehenden institutionellen Kunden im Gesundheitswesen volumenbasierte Preisanreize

Volumenstufe	Diagnosetests	Preisnachlass
Stufe 1	100-250 Tests/Monat	5 % Rabatt
Stufe 2	251–500 Tests/Monat	10 % Rabatt
Stufe 3	Über 500 Tests/Monat	15 % Rabatt

Entwickeln Sie gezielte Schulungs- und Supportprogramme für den aktuellen Kundenstamm

Schulungsbudget für 2023: 950.000 $

• Online-Schulungsmodule: 350.000 $
• Technische Workshops vor Ort: 400.000 US-Dollar
• Zertifizierungsprogramme: 200.000 US-Dollar

Verbessern Sie die Kundenbindung durch verbesserten technischen Support nach dem Verkauf

Größe des technischen Supportteams: 45 Spezialisten

Support-Kanal	Durchschnittliche Reaktionszeit	Kundenzufriedenheitsziel
Telefonsupport	2 Stunden	90%
E-Mail-Support	4 Stunden	85%
Online-Chat	1 Stunde	92%

SOPHiA GENETICS SA (SOPH) – Ansoff-Matrix: Marktentwicklung

Streben Sie nach behördlichen Zulassungen in weiteren europäischen und asiatischen Gesundheitsmärkten

SOPHiA GENETICS erhielt im Jahr 2022 die CE-IVD-Kennzeichnung für 14 genomische Lösungen. Aktuelle behördliche Zulassungen decken 35 Länder in Europa ab. Die Marktdurchdringung in Asien umfasst ab 2023 drei behördliche Zulassungen in Japan.

Region	Behördliche Genehmigungen	Marktpotenzial
Europa	35 Länder	4,2-Milliarden-Euro-Markt für Genomtests
Asien	3 Länder	2,7-Milliarden-Euro-Markt für Genomtests

Bauen Sie strategische Partnerschaften mit regionalen Diagnoselabornetzwerken auf

Das aktuelle Partnerschaftsportfolio umfasst über 750 Gesundheitseinrichtungen weltweit. Der Ausbau des Diagnosenetzwerks stieg im Jahr 2022 um 22 %.

• Nordamerika: 280 Diagnosepartnerschaften
• Europa: 310 diagnostische Partnerschaften
• Asien-Pazifik: 160 Diagnosepartnerschaften

Zielen Sie mit der wachsenden Infrastruktur für genomische Tests auf aufstrebende Märkte

Die Infrastruktur für genomische Tests in den Schwellenländern wird von 2023 bis 2028 voraussichtlich um 14,5 % CAGR wachsen. Zu den Zielmärkten zählen Indien, Brasilien und die Länder des Nahen Ostens.

Region	Marktgröße für Genomtests 2023	Prognostiziertes Wachstum
Indien	320 Millionen Euro	16,2 % CAGR
Brasilien	210 Millionen Euro	15,8 % CAGR

Entwickeln Sie lokalisierte Marketingstrategien für verschiedene geografische Regionen

Im Jahr 2023 wurden Marketinginvestitionen in Höhe von 4,3 Millionen Euro für die regionale Strategieentwicklung bereitgestellt. Die Lokalisierungsbemühungen konzentrieren sich auf sprachliche, kulturelle und Anpassungen des Gesundheitssystems.

Erstellen Sie regionalspezifische Produktkonfigurationen, die auf einzigartige Gesundheitsbedürfnisse zugeschnitten sind

F&E-Investitionen in Höhe von 12,7 Millionen Euro für Anpassungen der Produktkonfiguration im Jahr 2023. Das aktuelle Produktportfolio umfasst 22 spezialisierte Genomtestlösungen.

Region	Spezialisierte Lösungen	Fokus auf Individualisierung
Europa	8 Lösungen	Onkologische Präzision
Nordamerika	7 Lösungen	Erkennung seltener Krankheiten
Asien-Pazifik	7 Lösungen	Anpassung der genetischen Diversität

SOPHiA GENETICS SA (SOPH) – Ansoff Matrix: Produktentwicklung

Erweitern Sie KI-gesteuerte Diagnosealgorithmen für weitere Krankheitskategorien

SOPHiA GENETICS investierte im Jahr 2022 31,4 Millionen US-Dollar in Forschung und Entwicklung und konzentrierte sich dabei auf die Erweiterung der KI-Diagnosefunktionen über mehrere Krankheitsbereiche hinweg.

Krankheitskategorie	Aktuelle Algorithmusabdeckung	Geplante Erweiterung
Onkologie	12 Krebsarten	18 gezielte Krebsarten bis 2024
Seltene genetische Störungen	45 identifizierte Störungen	75 Erkrankungen bis Ende 2024

Entwickeln Sie umfassendere genomische Testpanels für die Präzisionsmedizin

SOPHiA GENETICS meldete im Jahr 2022 1.200 aktive klinische Standorte, die ihre Genomtestplattformen nutzten.

• Die Komplexität des Genompanels stieg von 500 auf 750 genetische Marker
• Die Genauigkeit des Präzisionsmedizintests wurde auf 96,4 % verbessert
• Die Testdurchlaufzeit wurde auf 5,2 Tage verkürzt

Investieren Sie in Verbesserungen des maschinellen Lernens für eine genauere genetische Interpretation

Die Investitionen in maschinelles Lernen erreichten im Geschäftsjahr 2022 12,7 Millionen US-Dollar.

ML-Erweiterungsbereich	Investition	Erwartete Genauigkeitsverbesserung
Variantenklassifizierung	4,3 Millionen US-Dollar	5,6 % Verbesserung
Prädiktive Modellierung	5,2 Millionen US-Dollar	7,2 % Verbesserung

Erstellen Sie spezialisierte Diagnoselösungen für aufstrebende genetische Forschungsbereiche

SOPHiA GENETICS hat seine spezialisierten Diagnoselösungen im Jahr 2022 mit 8,6 Millionen US-Dollar für neue Forschungsbereiche erweitert.

• Das genetische Screening neurologischer Störungen stieg um 42 %
• Das Pharmakogenomik-Panel wurde auf 120 genetische Marker erweitert
• Die Diagnosekapazitäten für seltene Krankheiten stiegen um 35 %

Integrieren Sie fortschrittliche Bioinformatikfunktionen in bestehende Produktlinien

Das Budget für die Bioinformatik-Integration belief sich im Jahr 2022 auf 16,9 Millionen US-Dollar.

Produktlinie	Verbesserung der Bioinformatik	Leistungsverbesserung
SOPHiA DDM-Plattform	Verbesserte Datenverarbeitungsalgorithmen	23 % schnellere Dateninterpretation
Genomisches Profiling	Erweiterte Variantenanmerkung	18 % erhöhte Diagnosegenauigkeit

SOPHiA GENETICS SA (SOPH) – Ansoff-Matrix: Diversifikation

Entdecken Sie genomische Datenanalysedienste für die pharmazeutische Forschung

SOPHiA GENETICS erzielte im Jahr 2022 einen Umsatz von 45,2 Millionen US-Dollar, wobei 92 kommerzielle Standorte ihre Genomdatenplattform nutzten. Das Unternehmen führte weltweit über 1 Million Genomtests in 580 Gesundheitseinrichtungen durch.

Metrisch	Wert
Globale Gesundheitseinrichtungen	580
Genomtests verarbeitet	1,000,000+
Kommerzielle Websites	92

Entwickeln Sie Beratungsdienste für die Implementierung von Gesundheitstechnologien

SOPHiA GENETICS investierte im Jahr 2022 23,7 Millionen US-Dollar in Forschung und Entwicklung und konzentrierte sich dabei auf fortschrittliche Beratungsdienste im Bereich Gesundheitstechnologie.

• F&E-Investitionen: 23,7 Millionen US-Dollar
• Schwerpunkte der Technologieberatung: Onkologie, seltene Krankheiten, Erbkrankheiten

Erstellen Sie Bildungsplattformen für die Ausbildung in genomischer Medizin

Das Unternehmen arbeitete mit 37 akademischen Einrichtungen zusammen, um im Jahr 2022 Schulungsprogramme für Genommedizin zu entwickeln.

Trainingsprogramm-Metriken	Nummer
Akademische Partnerschaften	37
Schulungsmodule entwickelt	12

Untersuchen Sie die mögliche Ausweitung der personalisierten Medizintechnologie

SOPHiA GENETICS meldete für das Jahr 2022 einen adressierbaren Gesamtmarkt in der Präzisionsmedizindiagnostik von 58 Milliarden US-Dollar.

• Marktgröße für Präzisionsmedizin: 58 Milliarden US-Dollar
• Zielwachstumsrate: 12,3 % jährlich

Erwägen Sie strategische Akquisitionen in komplementären Gesundheitstechnologiebereichen

Das Unternehmen verfügte zum 31. Dezember 2022 über 170,3 Millionen US-Dollar an Zahlungsmitteln und Zahlungsmitteläquivalenten, die möglicherweise für strategische Akquisitionen zur Verfügung standen.

Finanzkennzahl	Betrag
Zahlungsmittel und Zahlungsmitteläquivalente	170,3 Millionen US-Dollar
Mögliches Akquisitionsbudget	Bis zu 100 Millionen Dollar

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Market Penetration

You're looking at how SOPHiA GENETICS SA can deepen its hold in the markets it already serves, specifically with existing oncology and rare disease labs using the SOPHiA DDM platform. This is about getting more value from the customers you already have relationships with.

For existing US and European oncology labs, the penetration is showing momentum. As of September 30, 2025, SOPHiA GENETICS SA reached 488 core genomics customers, up from 462 customers at the end of Q3 2024. The U.S. market, in particular, is responding, delivering 30% year-over-year revenue growth in Q3 2025. In Europe, new adoption includes the Nice University Hospital in France, which is adopting MSK-ACCESS^® powered with SOPHiA DDM^TM in Q3 2025, and Jessa Ziekenhuis in Belgium, which adopted the platform in Q1 2025. The platform's overall analysis volume in Q3 2025 was a record 99,000 analyses, showing increased use across the installed base.

When looking at converting competitor users, the focus shifts to the value captured from new agreements. The average contract value of new signings in Q3 2025 increased by 180% year-over-year. This suggests that any aggressive pricing tiers, if offered, are being paired with larger, more comprehensive initial commitments or upsells that drive immediate, higher-value adoption rather than just small conversions.

Expanding clinical utility for existing rare disease customers is clearly happening through strategic application deployment. For instance, in Q2 2025, Igenomix, a global reproductive health and fertility reference lab, adopted SOPHiA DDM^TM for Rare and Inherited Disorder applications. Also in Q3 2025, Clinica MEDS in Chile adopted Rare Disorder applications. The broader Liquid Biopsy application, MSK-ACCESS^® powered with SOPHiA DDM^TM, had already attracted 34 leading institutions across the globe as of February 2025, indicating successful integration of new, high-value panels into existing customer workflows.

Driving higher data volume per existing client is tied directly to platform utilization and contract structure. The total analysis volume on SOPHiA DDM^TM in Q3 2025 was 99,000 analyses, which was a 9% year-over-year volume growth. For Q1 2025, the volume was 93,000 analyses, representing 11% year-over-year growth. Regarding service contract renewals, SOPHiA GENETICS SA recognizes revenue for its primary performance obligation, the delivery of analysis results, in most cases upon the issuance of the final report. However, some arrangements for software/database access are recognized on a straight-line basis over the duration of the agreement, which implies a recurring revenue component tied to the contract term, supporting sustained volume.

To drive utilization among current users, the results show organic growth in analysis volume, which is the direct output of utilization. The year-to-date analysis volume growth demonstrates the platform's increasing use within the installed base. The following table summarizes key volume and customer metrics from the first three quarters of 2025:

Metric	Q1 2025	Q2 2025	Q3 2025
Analyses Performed (Total)	93,000	95,000	99,000
YoY Analysis Volume Growth	11%	9%	9%
Core Genomics Customers (End of Period)	490	490	488
New Customers Signed (Period)	28	35	31

The growth in analysis volume, such as the 9% year-over-year increase in Q3 2025, reflects the success of efforts to increase platform utilization among existing users. The company also signed an impressive cohort of 31 new customers in Q3 2025.

• The U.S. market saw core genomics customer revenue grow over 30% in Q1 2025.
• North America revenue grew 24% year-over-year in Q2 2025.
• APAC analysis volume grew 35% year-over-year in Q3 2025.
• The total number of core genomics customers reached 488 as of September 30, 2025.

Finance: review Q4 2025 contract backlog conversion timing by next Tuesday.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Market Development

You're looking at how SOPHiA GENETICS SA is taking its existing SOPHiA DDM platform into new geographic territories and new customer segments. This is about expanding the reach of what you already have, which usually carries less product risk than developing something entirely new.

For the Japanese and South Korean clinical markets, the strategy involves navigating local regulatory hurdles and finding the right local champions. We saw a concrete step in Japan in October 2025 when A.D.A.M. Innovations, a leading private genetic testing company there, agreed to partner to bring liquid biopsy testing to the Japanese population using the platform. This kind of local agreement is key to unlocking these markets. While specific 2025 regulatory clearances for South Korea aren't public, the overall APAC region is showing serious traction, with analysis volume growth hitting 35% year-over-year in Q3 2025. That growth definitely suggests the groundwork for market entry is paying off in the broader region. It's a big market, and you need local expertise to win there.

Targeting large-scale national biobanks in the Middle East and Latin America relies on proving the platform's scalability. In Latin America, you already have established footholds that support this push. For instance, Dasa, the largest integrated healthcare network in Brazil, expanded its partnership in 2021, and in 2025, Seguros SURA Colombia adopted the MSK-ACCESS® solution for research initiatives. Furthermore, Bioma4me in Brazil went live on the SOPHiA DDM™ Platform in January 2024 to advance its genetic testing capabilities. These wins in Brazil and Colombia show the platform can handle complex, multi-site adoption, which is exactly what a national biobank requires. We just need to see the dollar value attached to those large-scale biobank contracts.

Adapting the platform for non-clinical research settings, specifically pharma R&D and academic consortia, is already yielding major financial results. The biggest contract in company history was signed in Q2 2025: a multi-year AI breast cancer partnership with AstraZeneca. That's a huge validation point for the platform's utility outside of routine clinical labs. Also, in November 2025, an agreement was announced with Complete Genomics to co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on their sequencing platform. This move directly targets the research infrastructure used by biopharma and academic groups, effectively expanding the addressable market without changing the core software.

Securing a major contract with a national healthcare system like the UK's NHS for population-scale genomics is a high-value target. While the first deal with the NHS was back in 2014, momentum continues, as the Royal Marsden Hospital joined as another NHS-related provider adopting SOPHiA DDM™ in Q1 2025. Population-scale projects are different; they require massive throughput and long-term commitment. We don't have a specific 2025 contract amount for a new, large-scale NHS deal, but the consistent engagement with key UK institutions suggests this remains a primary strategic avenue for market development.

Establishing a dedicated sales team for Southeast Asia is a logical follow-up to the strong performance already seen in the APAC region. As noted, Q3 2025 saw 35% year-over-year analysis volume growth in APAC, which is the highest regional growth rate reported for that quarter. This indicates a market that is rapidly adopting the technology. A dedicated team would be designed to convert this high-growth utilization into more formal, large-scale contracts, similar to the 31 new customers SOPHiA GENETICS landed globally in Q3 2025. You need boots on the ground when the market is this hot.

Here's a quick look at the key numbers underpinning this market development strategy as of late 2025:

Metric	Value (Latest Reported)	Context
Full Year 2025 Revenue Guidance	$75 to $77 million	Represents 15% to 18% year-over-year growth
Total Core Genomics Customers	488	As of September 30, 2025
Q3 2025 New Customers Signed	31	Up from 22 in Q3 2024
Q3 2025 APAC Analysis Volume Growth	35%	Year-over-year growth rate
Average New Contract Value Increase (YoY)	180%	Demonstrates success in winning larger accounts

The success in securing the largest contract in company history with AstraZeneca and the strong APAC volume growth suggest the Market Development strategy is gaining momentum. What this estimate hides is the exact revenue contribution from the newly penetrated Japanese market or the specific contract value from the NHS engagement.

Finance: draft 13-week cash view by Friday.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Product Development

You're looking at the engine room of SOPHiA GENETICS SA, where new products are built on the existing SOPHiA DDM™ platform. This is where the capital expenditure translates into future revenue streams, and frankly, the numbers show they are still heavily invested in building this out.

The commitment to this area is long-term; since 2011, SOPHiA GENETICS SA has invested over US$400 million to build its AI capabilities in healthcare. This investment fuels the development of new applications, like the proposed AI-powered diagnostic for early-stage Alzheimer's disease, which would expand the platform beyond its current focus areas of cancer and rare disorders.

For context on the platform's current scale, as of the third quarter of 2025, over 780 healthcare institutions use the SOPHiA DDM™ platform, analyzing over 350,000 patients per year. The platform itself processed a record 99,000 analyses in Q3 2025, marking a 9% year-over-year volume increase for that quarter.

Product development success is also seen in customer adoption of new modules, which directly relates to expanding utility, such as integrating a proprietary liquid biopsy analysis module for cancer recurrence monitoring. The MSK-ACCESS® application, which is a liquid biopsy offering, had already attracted 34 customers since its launch in Q2 2024, with the company completing implementation for a total of 15 MSK-ACCESS® customers who were set to ramp up usage throughout 2025. This focus on new applications is driving better deal value; the average contract value for new signings in Q3 2025 increased by 180% year-over-year.

The drive to onboard more users, which supports the development of models like federated learning for secure data sharing, is reflected in customer acquisition metrics. SOPHiA GENETICS SA landed 31 new core genomics customers in Q3 2025, up from 22 in Q3 2024, bringing the total core genomics customer count to 488 as of September 30, 2025.

Introducing a simplified user interface for non-genomics specialists is about broadening the user base, which is supported by the overall customer growth. The platform's utility is also expanding through strategic alliances, such as the major partnerships signed in Q3 2025 with AstraZeneca to develop an optimized next generation sequencing (NGS) solution and leverage multimodal AI Factories. This type of partnership, aimed at co-developing workflow solutions, underpins the financial outlook, with full-year 2025 revenue guidance reaffirmed in the range of $75 million to $77 million.

The financial performance of the platform, which is the base for all new products, shows an adjusted gross margin of 73.1% in Q3 2025.

Metric	Value (as of Q3 2025 or latest)	Context
FY 2025 Revenue Guidance Range	$75 million to $77 million	Full Year 2025 Projection
Q3 2025 Revenue	$19.5 million	Year-over-year growth of 23%
Q3 2025 Analyses on SOPHiA DDM™	99,000	Represents 9% year-over-year volume growth
Core Genomics Customers	488	As of September 30, 2025
New Core Genomics Customers Signed (Q3 2025)	31	Up from 22 in Q3 2024
Average Contract Value Increase (Q3 2025 New Signings)	180%	Year-over-year increase
Adjusted Gross Margin (Q3 2025)	73.1%	Indicates platform efficiency

The ongoing development efforts are supported by the platform's ability to scale, evidenced by the Q1 2025 milestone of passing 2 million cumulative genomic profiles analyzed since inception.

• Launch Alzheimer's application to expand beyond cancer and rare disorders.
• Integrate liquid biopsy module, building on the 34 MSK-ACCESS® customers signed by March 2025.
• Develop federated learning model to support the network of 488 core genomics customers.
• Introduce simplified UI to help non-genomics specialists use the platform.
• Partner for end-to-end workflow, building on Q3 2025 partnerships with AstraZeneca.

The Q3 2025 Adjusted EBITDA loss was $10.2 million, or an improved $8.8 million when excluding elevated Swiss social charges.

Finance: draft 13-week cash view by Friday.

SOPHiA GENETICS SA (SOPH) - Ansoff Matrix: Diversification

You're looking at how SOPHiA GENETICS SA can move beyond its core genomics analysis business, which saw Q3 2025 revenue hit $19.5 million, up 23% year-over-year. The full-year 2025 revenue guidance is set between $75 to $77 million, representing a 15% to 18% growth rate. This diversification is about planting seeds in new, adjacent markets.

Acquire a specialized clinical trial management organization (CTMO) to offer end-to-end drug development services.

This move leverages the existing customer base, which reached 488 core genomics customers as of September 30, 2025. The company signed 31 new core genomics customers in Q3 2025 alone, with the average contract value increasing by 180% year-over-year. Integrating CTMO services could capture more of the value chain from these growing client relationships.

Develop and market proprietary, in-house developed companion diagnostic (CDx) kits alongside the data analysis service.

The global oncology companion diagnostic market was valued at USD 5.09 billion in 2024 and is projected to reach USD 8.38 billion by 2030, growing at a Compound Annual Growth Rate of 9.02% from 2025 to 2030. SOPHiA GENETICS SA has already signaled intent to develop a liquid biopsy companion diagnostic (CDx) test in Japan with a partner that has conducted over 2.8 million genetic tests to date. This aligns with the segment where products accounted for 66.14% of the market share in 2024.

Launch a direct-to-consumer (DTC) genetic testing service focused on wellness and preventative health, leveraging the AI platform.

The platform has processed a record 99,000 analyses in Q3 2025, contributing to a cumulative total of over 2 million genomic profiles analyzed since inception as of Q1 2025. A DTC offering would tap into a broader consumer base, building on the platform's proven analytical scale. To be fair, this requires a different regulatory and marketing approach than the current B2B focus.

Establish a new business unit focused on providing regulatory consulting and data submission services for pharma clients.

The current financial reality shows a Q3 2025 Net IFRS loss of $20.0 million, with an Adjusted EBITDA loss of $10.2 million (or $8.8 million excluding elevated Swiss social charges, which is a 13% year-over-year improvement). High-value, low-cost-of-goods-sold services like regulatory consulting could help bridge the gap to the targeted Adjusted EBITDA breakeven by the end of 2026, especially given the full-year Adjusted EBITDA loss guidance of $39 to $41 million.

Invest in a new therapeutic area, like infectious disease surveillance, using the core data analysis technology.

The core technology is already handling complex multimodal data, as evidenced by the platform's use across oncology and rare disorders. Expanding into infectious disease surveillance would utilize the same analytical engine that supported 488 core genomics customers at the end of Q3 2025. This is a natural extension given the platform's ability to analyze data across different diagnostic modalities.

Here's a quick math check on the current state versus the growth trajectory you're aiming for:

Metric	Value (Q3 2025 or Guidance)	Context
Q3 2025 Revenue	$19.5 million	Quarterly performance
Full Year 2025 Revenue Guidance	$75 to $77 million	Expected annual top-line
Adjusted Gross Margin (Q3 2025)	73.1%	Platform efficiency
Core Genomics Customers (Sep 30, 2025)	488	Installed base size
Oncology CDx Market Size (2024)	USD 5.09 billion	Adjacent market opportunity
Target Adj. EBITDA Breakeven	End of 2026	Profitability timeline

Diversification into these areas supports the long-term vision, especially considering the existing customer engagement levels:

• Customers using two or more applications (end of 2024): 58%
• New customers signed in Q3 2025: 31
• Year-over-year analysis volume growth (Q3 2025): 9%
• APAC analysis volume growth (Q3 2025): 35%
• NORAM analysis volume growth (Q3 2025): 26%

The technology is ready for new data types; the question is which market entry point offers the best risk-adjusted return.

Finance: draft 13-week cash view by Friday.